News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
520,470 Results
Type
Article (16770)
Company Profile (171)
Press Release (503768)
Multimedia
Podcasts (14)
Webinars (7)
Section
Business (174865)
Career Advice (393)
Deals (26646)
Drug Delivery (22)
Drug Development (57684)
Employer Resources (25)
FDA (10575)
Job Trends (9429)
News (251519)
Policy (19435)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Genetown Elite (1)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (1066)
Accelerated approval (32)
ADA (26)
Adcomms (6)
Allergies (101)
Alliances (35886)
ALS (150)
Alzheimer's disease (1184)
Antibody-drug conjugate (ADC) (293)
Approvals (11168)
Artificial intelligence (389)
ASCO (177)
Autoimmune disease (222)
Automation (31)
Bankruptcy (271)
Best Places to Work (7694)
BIO (42)
Biologics (2)
BIOSECURE Act (3)
Biosimilars (117)
BioSpace Insights (26)
Biotechnology (119)
Bladder cancer (142)
Brain cancer (50)
Breast cancer (544)
Cancer (4060)
Cardiovascular disease (287)
Career advice (324)
Career pathing (3)
CAR-T (229)
CDC (1)
CDMO (34)
Celiac Disease (2)
Cell therapy (629)
Cervical cancer (35)
Clinical research (51487)
Collaboration (1480)
Commercialization (5)
Company closure (2)
Compensation (1502)
Complete response letters (46)
COVID-19 (1047)
CRISPR (98)
C-suite (840)
Cystic fibrosis (144)
Data (6388)
Denatured (5)
Depression (106)
Dermatology (70)
Diabetes (389)
Diagnostics (4927)
Digital health (39)
Diversity (2)
Diversity, equity & inclusion (10)
Drug discovery (206)
Drug pricing (12)
Drug shortages (2)
Duchenne muscular dystrophy (235)
Earnings (75251)
Editorial (11)
Employer branding (4)
Employer resources (24)
Events (92046)
Executive appointments (758)
FDA (13473)
Fibrodysplasia Ossificans Progressiva (11)
Friedreich's ataxia (21)
Frontotemporal dementia (30)
Funding (1100)
Gene editing (218)
Generative AI (13)
Gene therapy (592)
GLP-1 (381)
Government (1306)
Grass and pollen (3)
Guidances (294)
Healthcare (10431)
Hematology (115)
HIV (64)
Huntington's disease (45)
IgA nephropathy (75)
Immunology and inflammation (120)
Immuno-oncology (60)
Indications (169)
Infectious disease (1257)
Inflammatory bowel disease (144)
Inflation Reduction Act (5)
Influenza (86)
Intellectual property (266)
Interviews (51)
IPO (12783)
IRA (3)
Job creations (2137)
Job search strategy (310)
JPM (8)
Kidney cancer (16)
Labor market (4)
Layoffs (114)
Legal (5358)
Licensing (11)
Liver cancer (50)
Longevity (22)
Lung cancer (554)
Lymphoma (298)
Machine learning (35)
Management (4)
Manufacturing (605)
Marketing (9)
MASH (128)
Medical device (8770)
Medtech (8917)
Mergers & acquisitions (14933)
Metabolic disorders (856)
mRNA (114)
Multiple sclerosis (107)
NASH (5)
Neurodegenerative disease (302)
Neuropsychiatric disorders (48)
Neuroscience (2238)
NextGen: Class of 2026 (3571)
Non-profit (1430)
Now hiring (11)
Obesity (304)
Opinion (60)
Ovarian cancer (167)
Pain (185)
Pancreatic cancer (224)
Parkinson's disease (248)
Partnered (15)
Patents (503)
Patient recruitment (576)
Peanut (31)
People (43807)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (16888)
Phase 2 (22995)
Phase 3 (15687)
Pipeline (8047)
Policy (39)
Postmarket research (1671)
Preclinical (7315)
Press Release (44)
Prostate cancer (200)
Psychedelics (11)
Radiopharmaceuticals (194)
Rare diseases (971)
Real estate (3288)
Recruiting (8)
Regulatory (16326)
Reports (24)
Research institute (1252)
Resumes & cover letters (54)
Rett syndrome (50)
RNA editing (18)
RSV (50)
Schizophrenia (108)
Series A (182)
Series B (151)
Service/supplier (5)
Sickle cell disease (93)
Special edition (3)
Spinal muscular atrophy (157)
Sponsored (11)
Startups (2378)
Stomach cancer (3)
Supply chain (51)
Tariffs (2)
The Weekly (8)
Vaccines (406)
Venture capital (32)
Weight loss (113)
Women's health (89)
Date
Today (33)
Last 7 days (255)
Last 30 days (1546)
Last 365 days (20668)
2026 (13752)
2025 (21022)
2024 (25019)
2023 (28689)
2022 (37242)
2021 (39930)
2020 (35993)
2019 (25850)
2018 (19398)
2017 (20693)
2016 (19808)
2015 (26101)
2014 (22987)
2013 (19367)
2012 (21283)
2011 (21517)
2010 (21234)
Location
Africa (310)
Alabama (76)
Alaska (3)
Arizona (312)
Arkansas (12)
Asia (20444)
Australia (2679)
California (12671)
Canada (3292)
China (639)
Colorado (498)
Connecticut (453)
Delaware (218)
Europe (33082)
Florida (1841)
Georgia (395)
Hawaii (3)
Idaho (47)
Illinois (748)
India (55)
Indiana (496)
Iowa (17)
Japan (454)
Kansas (102)
Kentucky (35)
Louisiana (35)
Maine (31)
Maryland (1312)
Massachusetts (8585)
Michigan (310)
Minnesota (571)
Mississippi (4)
Missouri (88)
Montana (20)
Nebraska (14)
Nevada (116)
New Hampshire (61)
New Jersey (2721)
New Mexico (14)
New York (2969)
North Carolina (1364)
North Dakota (7)
Northern California (6415)
Ohio (320)
Oklahoma (14)
Oregon (21)
Pennsylvania (2374)
Puerto Rico (21)
Rhode Island (36)
South America (492)
South Carolina (77)
South Dakota (1)
Southern California (5162)
Tennessee (125)
Texas (2033)
United States (41467)
Utah (373)
Vermont (1)
Virginia (184)
Washington D.C. (43)
Washington State (1021)
West Virginia (1)
Wisconsin (85)
Wyoming (1)
520,470 Results for "atossa genetics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
July 21, 2026
·
7 min read
Press Releases
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
July 28, 2026
·
6 min read
Press Releases
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
June 11, 2026
·
5 min read
Press Releases
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
June 14, 2026
·
5 min read
Press Releases
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
May 4, 2026
·
7 min read
Press Releases
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 8, 2026
·
11 min read
Press Releases
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
May 21, 2026
·
6 min read
Press Releases
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
May 27, 2026
·
7 min read
Press Releases
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
March 19, 2026
·
6 min read
Press Releases
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
May 6, 2026
·
8 min read
1 of 52,047
Next
